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Abstract
Background: There is currently a lack of consensus for the diagnosis, investigations and treatments of acute
bacterial prostatitis (AP).
Methods: The symptoms, investigations and treatments of 371 inpatients diagnosed with AP were analyzed
through a retrospective study conducted in four departments – Urology (U), Infectious Diseases (ID), Internal
Medicine (IM), Geriatrics (G) – of two French university hospitals.
Results:  The cause of admission, symptoms, investigations and treatments depended markedly on the
department of admission but not on the hospital. In U, patients commonly presented with a bladder outlet
obstruction, they had a large imaging and functional check-up, and received alpha-blockers and anti-inflammatory
drugs. In ID, patients were febrile and received longer and more appropriate antibiotic treatments. In G, patients
presented with cognitive disorders and commonly had post-void urine volume measurements. In IM, patients
presented with a wide range of symptoms, and had very diverse investigations and antibiotic regimen.
Overall, a 3:1 ratio of community-acquired AP (CA-AP) to nosocomial AP (N-AP) was observed. Urine culture
isolated mainly E. coli (58% of AP, 68% of CA-AP), with venereal agents constituting less than 1%. The probabilistic
antibiotic treatments were similar for N-AP and CA-AP (58% bi-therapy; 63% fluoroquinolone-based regimen).
For N-AP, these treatments were more likely to be inadequate (42% vs. 8%, p < 0.001) and had a higher rate of
bacteriological failure (48% vs. 19%, p < 0.001).
Clinical failure at follow-up was more common than bacteriological failure (75% versus 24%, p < 0.001). Patients
older than 49 had more underlying urinary tract disorders and a higher rate of clinical failure (30% versus 10%, p
< 0.0001).
Conclusion: This study highlights the difficulties encountered on a daily basis by the physicians regarding the
diagnosis and management of acute prostatitis.
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Background
There is a current lack of agreement upon guidelines for
the diagnosis and treatment of male urinary tract infec-
tions (UTI), in particular concerning acute prostatitis
(AP). Indeed, the current NIH classification of prostatitis
provides a rather vague description of AP clinical symp-
toms, referred to as "signs of acute UTI" [1]. Some guide-
lines reached an agreement for the diagnosis of
uncomplicated UTI in male, while others considered that
"any UTI has a potential for a prostatic involvement"
[2,3]. In AP, some authors recommend to treat initially for
Neisseria gonorrhoaea and Chlamydiae trachomatis in young
adults [4]. Conversely, others recommend a treatment
only for Enterobacteriacae  [5]. The antibiotic treatment
duration varies from 10 days to 6 weeks [4,6]. This situa-
tion is different from UTI in women, where the guidelines
for the diagnosis and treatment are very similar in differ-
ent countries [4,2,7,8,5,6].
There is a need to analyze how clinicians from different
departments and backgrounds define AP before attempt-
ing to propose a consensus for AP management. Unlike
previously published studies that focused on highly
selected patients in urological settings or in prostatitis
centers, this study presents the analysis of a large group of
patients treated for AP in eight different departments of
two French university hospitals [9-11].
Methods
Study design
This study presents a retrospective analysis of AP diagno-
sis and global management. It was conducted in four
departments (Infectious Diseases, Urology, Internal Med-
icine, Geriatrics) of two French university hospitals for a
total of eight departments. In these departments, no insti-
tutional guidelines for the management of AP were avail-
able.
Patients
Patients with a final physician-assigned diagnosis of AP
were included in the study. They were admitted between
January 1st 1998 and December 31st 2003 to the above
listed departments, with the restrictions described below.
Patients preliminarily diagnosed with AP were selected
from the central database of each hospital. Patients with
uncompleted or missing chart were not included, neither
those where the final diagnosis was reported as being dif-
ferent from the preliminary diagnosis (i.e., mistake in data
capture).
Data collection and analysis
All the data was collected from the medical charts by the
same investigator (M.E.) using a computerized standard
form. The data stated and prescribed in the file by the phy-
sicians, the biological data, and the interpretation of the
specialist for any complementary investigation (i.e. radi-
ologist report for CT-scan) were recorded and analyzed.
The data included age, medical history, mode of acquisi-
tion, cause for admission, clinical symptoms, biological
and imaging investigations, antibiotic treatments, and
evolution after discharge. The number of co-morbidities
was documented; the most common being progressive
neoplasia, HIV infection, immunosuppressive therapy,
unstable diabetes mellitus, chronic alcoholism, and neu-
rological disorders affecting the micturition such as para-
plegia, dementia or a bedridden state. Haematuria at
admission was defined as macroscopic bleeding in urine
or blood detection in urine with a rapid strip test. For
urine analysis, a leukocyte count greater than 10/mm-3
and a bacterial count greater than 104 CFU/mL were con-
sidered to be significant [3]. The antibiotic treatment was
considered to be inadequate when the isolated strains
were resistant to all the antibiotics prescribed. The criteria
used for microbiological and clinical failure were those
defined in the IDSA/FDA guidelines for the evaluation of
new anti-infective drugs for the treatment of UTI [3]. A
microbiological treatment failure was defined as a posi-
tive urine culture (greater than 103 CFU/mL in a sympto-
matic patient or 105 CFU/mL in an asymptomatic patient)
at the follow-up visit 5–9 days or 4–6 weeks post-treat-
ment. A clinical treatment failure was defined as the pres-
ence of urinary symptoms at any time up to and including
the final follow-up visit.
Expression of results and statistical analysis
The results were expressed globally, according to the
department, to the community/nosocomial acquisition of
the infection, or to the age of the patients. Using guide-
lines established in the French consensus, nosocomial
UTIs included all urinary infections related to health care
facilities, either hospital-acquired or occurring among
outpatients with a urinary catheter [12]. The statistical
analysis was conducted with Statview® 5.0 software (SAS
Institute), using Khi-2 tests for quantitative data analysis,
and student t-test to compare qualitative and quantitative
data. To identify prognosis factors, a univariate analysis
was conducted using a logistic regression test. Significant
data were studied using a multivariate logistic regression
analysis. A categoritical analysis regression tree using JMP
software® (SAS Institute) was used to determine an age cut-
off significantly associated with an increased rate of clini-
cal failure at follow-up. For all statistical analysis, a p value
lower than 0.05 was considered to be significant.
Results
Patient inclusion
Between 1998 and 2003, 2170 male patients admitted in
the 8 above-mentioned departments presented a final UTI
diagnosis. Among them, 586 patients (27%) had a final
diagnosis of AP. The chart review resulted in the exclusionBMC Infectious Diseases 2008, 8:12 http://www.biomedcentral.com/1471-2334/8/12
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of 215 patients (130 missing or uncompleted files, 85
erroneous diagnosis codes). A total of 371 patients were
included in the study, 231 from Rouen University Hospi-
tal and 154 from Dijon University Hospital, accounting
for a 6:4 ratio in accordance with the respective size of the
Rouen and Dijon population areas. The distribution of
the patients, among the 4 departments and between the
hospitals, was homogenous from one year to another,
with 48% of the patients in Urology, 31% in Infectious
Diseases, 13% in Internal Medicine and 8% in Geriatrics.
Clinical history and symptoms
The mode of contamination and the medical history ver-
sus the department are presented in Table 1. Regardless of
the department (and the hospital, data not shown), a 3/1
ratio was observed between community-acquired (CA-
AP) and nosocomial (N-AP) acute prostatitis. In contrast,
the medical history varied between the departments in
regards to age, the number of co-morbidities and the uro-
logical background. As presented in figure 1, 50% of the
patients were over 65 years old whereas 10% were under
35. A past history of UTI was noted in 37% of the patients
who were treated with antibiotics on an average duration
of 9 days, and a prostatic involvement was specifically
noted in 40% of these patients. The following trends in
the causes of admission and the clinical symptoms during
the course of the disease were noted throughout the differ-
ent departments: urinary symptoms in Urology, fever and
chills in Infectious Diseases, cognitive disorders in Geriat-
rics, and variable symptoms such as malaise or weight loss
in Internal Medicine. They are presented in Table 2.
Microbiological investigations, PSA and CRP evaluation
Urine analysis was performed for 347 (94%) patients.
Among the 122 samples that generated sterile urine cul-
tures (35%), 55 (45%) were taken during antibiotic treat-
ment, and 83 (68%) showed a significant leukocyte
count. Among the 225 samples that generated positive
urine culture (65%), 19 (8%) were taken during antibiotic
treatment, and all but one showed a significant leukocyte
count. Table 3 displays the bacteriological results of urine
cultures versus the mode of contamination. Escherichia coli
was the main pathogen, representing 58% of the isolated
bacteria. Only 26% of the isolated strains in the N-AP
cases were E. coli. Antibiotic-resistant strains, either natu-
rally (Pseudomonas aeruginosa, Enterococcus sp) or through
acquired mechanisms (quinolone-resistant E. coli) were
statistically more common for N-AP. A urethral swab was
performed for 9 patients and the following results were
noted: 3 were sterile, 3 generated the isolation of more
than 5 microbial species, 2 generated the isolation of
Chlamydiae trachomatis, and one generated the isolation of
E. coli. The Meares and Stamey diagnosis localizing test
("four-glass" test) was performed on 3 patients [13]. In
one case, the test was performed despite a previous posi-
tive urine analysis (103 Enterococcus faecalis/mL-1, and 104
leukocytes/mL-1). In the two remaining cases and despite
the absence of leukocytes and bacteria in the urine sam-
ples, the patients were diagnosed with AP on the basis of
acute urinary symptoms and fever.
Blood cultures were performed for 260 patients (70%)
and were positive for 120 of them. For 70 patients (19%),
Table 1: Mode of contamination and medical history of 371 patients with acute prostatitis
Total patients Department of admission
Urology Infectious Diseases Internal Medicine Geriatrics
n = 371 N = 178 n = 115 n = 48 n = 30
Mode of contamination
Community-acquired 293 (79%) 140 (79%) 91 (79%) 41 (86%) 21 (71%)
Nosocomial 78 (21%) 37 (21%) 24 (21%) 7 (14%) 9 (29%)
Hospital acquisition 58 (75%) 26 (69%) 18 (75%) 5 (72%) 8 (87%)
Outpatient with urinary catheter 20 (25%) 11(31%) 6 (25%) 2 (28%) 1 (13%)
Medical history
Age (years)
Median 61 57 60 66 84
Range 18–99 19–96 18–88 22–99 69–96
Number of co-morbidities
≤ 1 345 (93%) 175 (98%) 113 (98%) 33 (69%) 23 (78%)
≥ 2 26 (7%) 3 (2%) 2 (2%) 15 (31%) 7 (22%)
Urological background
Past history of UTI 137 (37%) 53 (30%) 58 (50%) 21 (43%) 6 (19%)
Urinary drainage before admission 42 (11%) 23 (13%) 12 (10%) 4 (8%) 2 (7%)
Past history of anatomical urological disorder 45 (12%) 25 (14%) 14 (12%) 4 (8%) 7 (23%)
Past history of neurological bladder 60 (16%) 18 (10%) 15 (13%) 14 (30%) 12 (40%)BMC Infectious Diseases 2008, 8:12 http://www.biomedcentral.com/1471-2334/8/12
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the isolated strain was an enterobactaeriacae, the same
strain as in the urine culture. For 50 patients, a single
blood culture isolated a coagulase-negative Staphylococcus,
suggesting contamination.
The prostatic specific antigen (PSA) was measured for
44% of the patients, on an average of the 4th day of admis-
sion, range [0–12], and revealed an abnormality (> 4 mg/
L-1) in 60% of the cases (median value 17 mg.L-1; range
[0–415]). Most patients had an inflammatory syndrome:
70% of the patients had more than 10,000 WBC (median
of 12.7 G/L-1, range [800–38100]), 95% of the patients
had an erythrocyte sedimentation rate at the first hour
exceeding 10 mm (median 60 mm, range [4–120]), and
96% presented a C Reactive Protein (CRP) exceeding 5
mg/L-1(median 123 mg/L-1; range [<5–445]).
Imaging and functional investigations
As presented in Table 4, the percentage of patients under-
going imaging or functional investigations of the prostate
displayed a marked variation depending on the depart-
ment. Out of the 371 included patients, 285 (77%) under-
went a pelvic or prostatic ultrasound (US) investigation
during their hospital stay (218 supra-pubic and 67 endo-
rectal US). The prostatic US was considered abnormal for
228 patients (81%) with the following descriptions: pros-
tatic hypertrophy (n = 127), prostatic calcifications (n =
69), ureteral dilation (n = 21), incomplete micturition (n
= 20), prostatic tumor (n = 15), or prostatic abscess (n =
10). Incomplete micturition was specifically investigated
by post-voiding pelvic US for 60 patients (21%), and was
considered abnormal for 36 (60%). Other imaging inves-
tigations performed included: abdomen X-ray (n = 48,
13%), intravenous urography (n = 48, 13%), retrograde
cystography (n = 22, 6%), uro CT-scan (n = 11, 3%), cys-
toscopy (n = 7, 2%). An uroflow measurement was per-
formed after discharge for 122 patients (33%) and was
abnormal in 61 (50%) of them. Overall, 182 patients
underwent a post-voiding residual urine or an uroflow
Distribution of 371 patients with acute prostatitis (AP)  according to their age and to the mode of contamination Figure 1
Distribution of 371 patients with acute prostatitis (AP) 
according to their age and to the mode of contamination.
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Table 2: Causes of admission and clinical symptoms during the course of the disease of 371 patients with acute prostatitis (AP).
Total patients Department of admission
Urology Infectious Diseases Internal Medicine Geriatrics
n = 371 n = 178 n = 115 n = 48 n = 30
Cause of admission
Fever 297 (80%) 142 (80%) 97 (84%) 37 (78%) 19 (63%)
Urinary symptoms
Functional symptoms 266 (72%) 153 (86%) 69 (60%) 27 (57%) 15 (50%)
Bladder outlet obstruction 61 (23%) 52 (29%) 9 (8%) 12 (25%) 6 (20%)
Cognitive disorder 14 (4%) 0 (0%) 5 (4%) 4 (8%) 10((33%)
Miscellaneous symptoms 28 (8%) 0 (0%) 2 (2%) 21 (44%) 7 (23%)
Main clinical symptoms during the course of AP
Fever 297 (80%) 154 (84%) 86 (80%) 38 (78%) 19 (63%)
Chills 135 (35%) 47 (25%) 60 (56%) 14 (28%) 7 (23%)
Urinary symptoms 266 (72%) 158 (86%) 65 (60%) 28 (57%) 15 (50%)
- burning micturition 143 (54%) 79 (50%) 36 (55%) 23 (82%) 5 (33%)
- pollakiuria 200 (52%) 77 (49%) 35 (54%) 18 (64%) 9 (60%)
- dysuria 79 (30%) 53 (34%) 15 (23%) 7 (25%) 4 (27%)
- bladder outlet obstruction 61 (23%) 46 (29%) 5 (8%) 7 (25%) 3 (20%)
- macroscopic haematuria 46 (17%) 33 (21%) 9 (14%) 2 (7%) 2 (13%)
Pelvic pain 144 (43%) 98 (58%) 27 (28%) 18 (42%) 1 (4%)
Abnormal digital rectal examination 235 (83%) 135 (89%) 55 (70%) 25 (83%) 20 (91%)
- painful prostate palpation 175 (63%) 115 (77%) 31 (39%) 15 (50%) 14 (64%)
- prostatic hypertrophy 152 (54%) 86 (57%) 36 (46%) 16 (53%) 14 (63%)
- prostate irregularity 66 (24%) 44 (30%) 10 (13%) 4 (13%) 8 (22%)BMC Infectious Diseases 2008, 8:12 http://www.biomedcentral.com/1471-2334/8/12
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measurement, and an abnormality was detected in 97 of
them (53%).
Treatment
Table 5 presents the antibiotic treatments, their adequacy
as determined by the results of urine culture, and the rates
of microbiological and clinical failures versus the acquisi-
tion mode and the department. Half of the patients were
initially treated with a combination of antibiotics, regard-
less of the contamination mode of AP. More than 80% of
the combinations included aminoglycosides; 56% of the
combinations included a 3rd generation cephalosporin
and an aminoglycoside. 225 patients (65%) had positive
urine cultures for which the treating physician adapted the
antibiotic treatment in 59 cases (16%) based on strain
susceptibility. The empirical and adapted antibiotic treat-
ments were inadequate for 16% and 7%, respectively, of
the total patients. The proportion of inadequate antibiotic
treatments showed marked variations depending on the
contamination mode of the AP and the department. The
median duration of the treatment was 34 days, signifi-
cantly longer in Infectious Diseases than in Urology (49
days versus 22 days).
Alpha-blockers and anti-inflammatory drugs were the
most commonly used concomitant medications, in 35
and 20%, respectively. Most of these medications were
prescribed in the Urology department. A bladder outlet
obstruction was present in 90 patients (25%); 45 patients
had urine drainage with a Foley catheter and 45 with a
supra pubic catheter, without any significant variation in
the proportion of bacteraemia (35% vs. 32%, p = 0.9).
Ten abscesses were cured surgically in Urology (9 from
patients with CA-AP and 1 from a patient with N-AP).
Table 4: Percentage of patients undergoing biological, imaging and functional investigations versus admission department
Total patients Department of admission
Urology Infectious Diseases Internal Medicine Geriatrics
n = 371 n = 178 n = 115 n = 48 n = 30
PSA dosage 163 (44%) 69 (39%) 52 (45%) 27 (55%) 15 (50%)
Pelvic ultrasound 286 (77%) 128 (72%) 105 (91%) 32 (67%) 22 (73%)
Post-void urine measurement 78 (21%) 37 (21%) 16 (14%) 7 (15%) 18 (59%)
Uroflow measure 122 (33%) 77 (43%) 9 (8%) 0 (0%) 0 (0%)
Other investigations* 152 (41%) 85 (48%) 15 (13%) 3 (6%) 3 (11%)
*Other investigations: abdomen X-ray, intravenous urography, retrograde cystography, uro-CT-scan, and cystoscopy.
Table 3: Bacteriological results of urine cultures versus mode of contamination in a series of 371 acute prostatitis (AP)
Bacteriological results of urine cultures
Total patients Community-acquired AP Nosocomial AP Community-acquired versus 
nosocomial AP
n = 371 n = 295 n = 76 p value
Urine culture 347 (94%) 271 (92%) 76 (100%) 0.02
Sterile 122 (35%) 96 (35%) 29 (38%) 0.71
Positive 225 (65%) 178 (66%) 47 (62%) 0.71
One strain 196 (87%) 159 (89%) 37 (79%) 0.09
≥ 2 strains 29 (13%) 19 (11%) 10 (21%) 0.09
Isolated strains 270 213 (79%) 57 (21%) < 0.001
E. coli
All types 157 (58%) 142 (68%) 15 (26%) < 0.01
Ampicillin-S 95 (61%) 88 (62%) 7 (50%) 0.4
Nalidixic acid-S 119 (76%) 110 (78%) 9 (57%) 0.2
Ofloxacin-S 130 (83%) 120 (85%) 10 (64%) 0.2
Cotrimoxazole-S 122 (78%) 115 (81%) 7 (43%) < 0.01
Proteus 16 (6%) 11 (5%) 5 (9%) 0.5
KES group 24 (9%) 18 (8%) 6 (11%) 0.8
Enterococcus 16 (6%) 8 (4%) 8 (14%) 0.02
P. aeruginosa 20 (7%) 8 (4%) 12 (21%) < 0.01
S. aureus 8 (3%) 3 (1%) 5 (9%) 0.02
Others 29 (11%) 23 (11%) 6 (11%) 0.9BMC Infectious Diseases 2008, 8:12 http://www.biomedcentral.com/1471-2334/8/12
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Course evolution and follow-up
Apyrexia was obtained on average 2.5 days after the start
of the treatment, with no significant variation depending
on the department. The median duration of hospital stay
was 9 days, and varied significantly according to the mode
of acquisition (8 days for CA-AP vs. 14 days for N-AP) and
the department (6 days in Urology, 21 days in Geriatrics).
The main early complications were severe sepsis (7% of
the patients) and prostatic abscess (4%). Twelve patients
(3%) died during their stay, 9 with CA-AP (3%), and 3
with N-AP (4%), however the cause of death was not
severe sepsis. The rates of bacterial and clinical failure dur-
ing follow-up are presented in Table 5. Two hundred and
sixty four patients (71%) attended a follow-up consulta-
tion after discharge, on an average of 35 days after the start
of treatment. The results of the 153 available urine cul-
tures performed at follow-up are presented in Table 5.
Positive urine cultures at follow-up were significantly
more frequent in patients with N-AP than CA-AP, in
patients from Geriatrics than other departments, and in
patients with a previous history of UTI (p < 0.01). Infor-
mation about functional urinary symptoms at follow-up
was available for 183 patients (Table 5). 137 (75%)
patients described the persistence of urinating pain, dis-
comfort, or both, without any significant difference
depending on the department. Eighty-five patients
attended a second follow-up consultation, with 80%
reporting urinary symptoms. Hospital admission in the
Infectious Diseases department was associated with a
lower proportion of empirically inadequate antibiotic
treatment, a longer total duration of treatment, and a
lower rate of bacteriological failure than in the other
departments; however, the rate of clinical failure was not
significantly different. An increased clinical cure rate was
associated with the presence of two symptoms at admis-
sion: haematuria or painful digital rectal examination. A
decreased bacteriological cure rate was associated with
various underlying urological disorders or with other fac-
tors such as inadequate empirical antibiotic treatment
(Table 6).
Impact of age on signs, symptoms, investigations, and 
outcome
Using a categoritical analysis regression tree, among the
264 patients that had a follow-up visit after discontinua-
tion of the treatment, we have noted that an age above 49
was significantly associated with a higher risk of clinical
failure at follow-up (90% versus 60%; p < 0.0001). The
signs, symptoms and the results of investigations were
analyzed among patients below and above 49. Older
patients had significantly more nosocomial infections,
more co-morbidities, a history of more frequent UTIs,
more urinary retention requiring urine drainage and more
underlying urological disorders (higher prostatic volume
Table 5: Antibiotic treatment and rates of microbiological and clinical failure versus mode of contamination and department in a 
series of 371 acute prostatitis (AP).
371 AP patients
Total patients Community
acquired AP
Nosocomial AP Community
acquired Versus
nosocomial AP
Urology Infectious
Diseases
Internal
Medicine
Geriatrics
n = 371 n = 293 n = 78 p value n = 178 n = 115 n = 48 n = 30
Antibiotic treatment
Empirical choice
Bi-therapy 215 (58%) 172 (59%) 43 (55%) 0.7 123 (69%) 63 (55%) 20 (42%) 9 (30%)
Use of fluoroquinolone 234 (63%) 187 (64%) 47 (60%) 0.7 148 (83%) 47 (41%) 20 (42%) 19 (63%)
Use of 3rd generation 
cephalosporin
113 (30%) 85 (29%) 28 (36%) 0.3 25 (14%) 59 (51%) 22 (46%) 7 (23%)
Use of amino glycosides 195 (52%) 165 (56%) 30 (38%) 0.007 120 (67%) 60 (52%) 14 (29%) 1 (3%)
Use of other classes 44 (12%) 28 (10%) 16 (21%) 0.01 8 (4%) 12 (10%) 12 (25%) 12 (40%)
Inadequate* 42/269 (16%) 17/210 (8%) 25/59 (42%) <0.001 27/137 (20%) 4/76 (5%) 6/31 (19%) 5/25 (25%)
Adapted choice
Bi-therapy 15 (4%) 13 (4%) 2(3%) 0.7 3 (2%) 11 (10%) 0 (0%) 1 (3%)
Use of fluoroquinolone 285 (77%) 242 (82%) 43 (55%) <0.001 148 (83%) 85 (74%) 31 (65%) 21 (70%)
Use of 3rd generation 
cephalosporin
18 (5%) 11 (4%) 7 (9%) 0.1 9 (5%) 1 (1%) 5 (10%) 3 (10%)
Use of cotrimoxazole 52 (14%) 44 (15%) 8 (10%) <0.001 13 (7%) 33 (29%) 5 (10%) 1 (3%)
Use of other classes 31 (8%) 9 (3%) 22 (28%) <0.001 11 (6%) 7 (6%) 7 (15%) 6 (20%)
Inadequate* 18/269 (7%) 11/210 (5%) 7/59 (12%) 0.1 14/137 (10%) 1/76 (1%) 1/31 (3%) 2/25 (8%)
Total duration (days) 32 34 29 0.13 22 49 33 33
Bacterial failure at follow-up 37/153 (24%) 23/124 (19%) 14/29 (48%) 0.002 16/76 (21%) 2/32 (6%) 1/6 (16%) 4/9 (44%)
- same strain 7 3 4 8 0 0 0
- other strain 30 20 10 8 2 1 4
Clinical failure at follow-up 137/183 (75%) 98/135 (73%) 39/48 (83%) 0.3 88/123 (71%) 28/36 (78%) 8/10 (80%) 13/14 (92%)
* The adequacy of the treatment was studied for the 169 patients with a positive urine culture and an antibiotic-resistance pattern of the pathogenic 
strain.BMC Infectious Diseases 2008, 8:12 http://www.biomedcentral.com/1471-2334/8/12
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at DRE and US examination, higher PSA levels, more nod-
ules at DRE, higher rate of abnormal uroflow measures).
Older patients also had fewer signs and symptoms (less
burning micturition, less painful DRE, and less hematu-
ria). Although underlying urological disorders are signifi-
cantly more common in older patients, the age was
associated with clinical failure at follow-up in univariate
and multivariate analysis (Table 6).
Discussion
This study highlights the difficulties encountered on a
daily basis by physicians regarding the diagnosis and
management of acute prostatitis.
A wide spectrum of clinical features leads to the diagnosis
of AP. Indeed, the accuracy of the physician's diagnosis of
acute prostatitis may be questioned: some of the patients
Table 6: Risk factors for clinical and bacteriological failure
Clinical failure*
Univariate analysis Multivariate analysis Odds ratio
PP
Personal history
Age < 0.001 < 0.001 1.040
history of prostate hyperplasia 0.024 NS** ND†
neurological bladder 0.033 NS** ND†
number of co-morbidities 0.004 NS** ND†
Symptoms
urinary symptoms 0.013 NS** ND†
haematuria 0.005 0.012 0.320
painful digital rectal examination 0.014 0.017 0.340
Underlying urinary tract pathology
discovery of prostate hyperplasia 0.005 NS** ND†
other anatomical or functional pathology < 0.001 0.013 4.720
Management
Anti inflammatory treatment 0.003 0.003 0.350
Bacteriological failure††
Univariate analysis Multivariate analysis Odds ratio
PP
Personal history
Age 0.001 0.002 1.060
history of urinary catheter 0.001 0.010 4.612
neurological bladder 0.002 NS** ND†
number of co-morbidities 0.044 NS** ND†
Symptoms
pollakiuria 0.006 NS** ND†
Dysuria 0.047 NS** ND†
bladder outlet obstruction 0.004 NS** ND†
Biology
Pseudomonas aeruginosa infection 0.006 0.013 7.279
infection with 2 or more strains 0.001 0.008 5.329
Imaging
prostate nodular lesion on ultrasound 0.005 NS** ND†
post void residual urine on ultrasound 0.001 NS** ND†
other anatomical or functional pathology 0.004 NS** ND†
Management
inadequate probabilistic antibiotic treatment < 0.001 0.002 4.570
urinary drainage with Foley catheter 0.002 NS** ND†
urinary drainage with supra pubic catheter 0.039 NS** ND†
*Clinical failure: patient reporting persistent clinical symptoms at the follow-up visit.
** NS: Not Significant, †ND: Not Determined
††Bacteriological failure: positive urine culture at the follow-up visit.BMC Infectious Diseases 2008, 8:12 http://www.biomedcentral.com/1471-2334/8/12
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may present with a pyelonephritis without prostatitis
while others (with urinary symptoms and sterile urine cul-
tures) may have chronic abacterial prostatitis. The main
clinical features reported on admission tend to vary
between the departments because of the recruitment crite-
ria used in each department (fever in Infectious Diseases,
urinary symptoms in Urology etc). The results of this
study clearly highlight the variations in the definition of
AP among departments and practitioners, and raise the
question: what are the key symptoms of AP? There is, sur-
prisingly, no evidence-based answer. The NIH revised
classification of prostatitis deals with pathophysiology
and biological diagnosis, but the clinical features of AP are
briefly described as "signs of acute UTI" [1]. Three recent
publications retain fever and urinary symptoms as the
diagnostic criteria, while prostatic pain at digital rectal
examination occurred in 9 to 100% of patients [14-16].
In regards to biological tests, the NIH revised classifica-
tion of prostatitis does not include the "four-glass-test" as
a criteria for AP diagnosis [1]. Moreover, prostatic mas-
sage is not recommended during the early phase of AP,
because it is painful for the patient and may lead to bacter-
aemia and sepsis [17]. In fact, none of the only three
"four-glass test" performed in this series contributed to
the diagnosis.
No routine clinical, biological or imaging test can cur-
rently provide evidence that adequately rules out prostatic
involvement in male UTI. While the European guidelines
reached a consensus about the diagnosis of "uncompli-
cated UTI in male," the French guideline and one Ameri-
can guideline consider that "any UTI in male has the
potential for a prostatic involvement" [5,2,3]. Two recent
imaging studies – one performed with prostatic Indium-
labeled leukocyte scintigraphy and one performed with a
combination of PSA levels and transrectal US-provided
evidence supporting a frequent involvement of the pros-
tate in male UTI [14,18]. Both publications report the
presence of an inflammatory reaction within the prostate
in 90% of cases, even when digital rectal examination was
not painful, or when the physician diagnosed an acute
pyelonephritis without prostatitis. These data support pre-
vious studies reporting a turbulent urine flow in the pros-
tatic urethra, associated with a reflux into the
perpendicular, wide open canals of the peripheral zone of
the prostate [19,20]. All these statements underline the
need to define detailed and consensual diagnosis criteria
of acute (i.e. NIH type 1) prostatitis, which would be help-
ful in AP management as well as in study standardization.
However, such a goal cannot be reached through a retro-
spective study.
The spectrum of microbial etiologies reported in our study
is similar to those found in complicated female UTI, both
in the case of community-acquired infections (two third
of Enterobacteriacae sp, 5–10% of Enterococcus sp and P. aer-
uginosa) as well as for nosocomial infections (large pro-
portion of resistant bacteria) [21,22]. This pattern has
been extensively described in the literature for chronic
prostatitis [23-25]. However, in the case of AP, there is
large variation in the ratio of pathogens reported in the lit-
erature, mainly depending on the detection method:
some publications reported up to 57% of Enterococcus
while others reported up to 40% of N. gonorrhoeae
[26,27]. The prevalence of venereal agents in our study
was low, even in male patients under 35 (2%). An under-
estimation of their representation due to a lack of specific
investigation seems unlikely, considering the high rate of
positive standard cultures in this age group; this rate is
very similar to the rate observed in other age groups. These
results are in accordance with recent studies reporting a
low prevalence of venereal micro-organisms, and do not
support the recommendations suggesting to treat first for
Neisseiria gonorrhea and Chlamydiae trachomatis in young
adults [28,29,26,30,4].
Finally, a striking 75% rate of clinical failure was noticed
in our study. This high value is to be handled carefully,
due to the large number of patients not attending follow-
up consultation. However, despite the higher incidence of
resistant micro-organisms in N-AP than in CA-AP, the
empirical antibiotic treatments prescribed in both cases
were similar, leading to inadequate antibiotic treatment
in 42% of the cases and a higher rate of bacteriological
failure. Moreover, the clinical failure rate being much
higher than the bacteriological failure rate suggests that
antibiotic treatment frequently induces an incomplete res-
olution of the symptoms, even without any early infection
relapse, possibly because of a persistent underlying uro-
logical disorder. This finding is supported by a previous
urological study of AP, where abnormalities requiring sur-
gical correction were detected in 24% of the patients after
a check-up including digital rectal examination, prostatic
ultrasound, post-void residual urine measurement and
uroflow measurement [18]. In our study, even though
uroflow or post-void residual urine measurement were
performed in only 33% of the patients, half of them were
abnormal. Patients older than 49 had both higher rates of
clinical failure and higher rates of underlying urological
disorders, and thus might be the target population for
prostate-centered investigations. Surprisingly, in our
study, initial haematuria, and painful digital rectal exam-
ination at admission were associated with a better clinical
outcome and were more common in younger patients.
Our hypothesis is that the above symptoms are fully
related to the infection (i.e., not to an underlying abnor-
mality of the prostate), and therefore are easier to control
with the appropriate antibiotic treatment.BMC Infectious Diseases 2008, 8:12 http://www.biomedcentral.com/1471-2334/8/12
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Conclusion
In conclusion, this study conducted among inpatients
admitted to different hospital units and diagnosed with
AP, shows that the clinical features associated with this
common infection vary between departments and clini-
cians. Patients receive different treatments depending on
the various departments but overall similar among differ-
ent hospitals. This heterogeneity in diagnosis criteria and
management of AP reflects both the lack of consensual
vision in the literature and the difficulties encountered on
a daily basis by the physicians.
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